NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
5/8 — Partial
FEMLYV (norethindrone acetate/ethinyl estradiol) by Millicent Pharma is ovulation. Approved for pregnancy () limitations of use the efficacy in females of reproductive potential with a body mass index of more than 35 kg/m has not been evaluated (. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FEMLYV is an oral contraceptive combining norethindrone acetate and ethinyl estradiol in an orally disintegrating tablet formulation. It prevents pregnancy by suppressing ovulation and is indicated for contraception in females of reproductive potential. The product was approved by the FDA on July 22, 2024, representing a novel dosage form in the established oral contraceptive market.
Growth14.6 years to LOE
Early-stage product with significant runway; commercial team likely to expand as market penetration increases and formulary access widens.
Mechanism of Action
ovulation.
Career Relevance
FEMLYV represents an early-career opportunity in a growth-stage contraceptive product with extended patent protection and minimal competitive threats. Roles focus on market development, formulary access, and provider/patient awareness rather than late-stage optimization.
Worked on FEMLYV at Millicent Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.